LOGIN  |  REGISTER
Amneal Pharmaceuticals
Chimerix

ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 26, 2023 | Last Trade: US$61.46 1.80 -2.85

BAUDETTE, Minn. / Apr 26, 2023 / Business Wire / ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ Headquarters in New York City as follows:

Date:      Tuesday, May 2, 2023
        
Time:      12:00 p.m. ET
        
Webcast:      Click Here

The webcast will be accessible on demand beginning on May 3, 2023, at 7:00 a.m. ET and archived for 90 days thereafter, via the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.

Astria Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page